Global biomarker trends in Alzheimer's research: A bibliometric analysis

Kenta Noda; Yeongjoo Lim; Shintaro Sengoku; Kota Kodama

doi:10.1016/j.drudis.2023.103677

Global biomarker trends in Alzheimer's research: A bibliometric analysis

Drug Discov Today. 2023 Aug;28(8):103677. doi: 10.1016/j.drudis.2023.103677. Epub 2023 Jun 28.

Authors

Kenta Noda¹, Yeongjoo Lim², Shintaro Sengoku³, Kota Kodama⁴

Affiliations

¹ Graduate School of Design and Architecture, Nagoya City University, Nagoya 464-0083, Japan.
² Ritsumeikan University, Osaka 567-8570, Japan.
³ School of Environment and Society, Tokyo Institute of Technology, Tokyo 108-0023, Japan.
⁴ Graduate School of Design and Architecture, Nagoya City University, Nagoya 464-0083, Japan; Ritsumeikan University, Osaka 567-8570, Japan; School of Data Science, Nagoya City University, Nagoya 467-8501, Japan; Center for Research and Education on Drug Discovery, The Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan. Electronic address: kkodama@fc.ritsumei.ac.jp.

PMID: 37390962
DOI: 10.1016/j.drudis.2023.103677

Abstract

Alzheimer's disease (AD) has no effective treatment, although antibody drugs targeting beta-amyloid, mainly aducanumab, have produced useful clinical results. Biomarkers can be used to determine drug regimens effectively and to monitor the effects of drugs. A concept in which biomarkers reflect disease states is emerging. Although several AD biomarker studies have been reported, measurement methods and target molecules are still being validated, and various biomarkers are being explored. This study analyzed trends in research on AD biomarkers using bibliometric methods, revealing an exponential increase in research reports in this field, with the US most active in research. Analysis of the 'Burst' biomarkers using CiteSpace revealed that networks centered on authors, rather than networks among countries, drive new research trends in this area.

Keywords: Alzheimer’s disease; biomarker research; dementia.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Alzheimer Disease* / drug therapy
Amyloid beta-Peptides
Biomarkers
Humans

Substances

Amyloid beta-Peptides
Biomarkers